Institut fuer Diabetesforschung Muenster GmbH
- Address
- lock Available on a paid plan
Hormonal Diseases and Nutritional and Metabolic Diseases
At Institut fuer Diabetesforschung Muenster GmbH, clinical research in diabetes focuses on improving care for people with Type 2 Diabetes and related metabolic conditions. The trials are designed to assess how well new treatments can lower blood sugar, support weight management, and improve overall disease control.
- Testing new therapies for Type 2 Diabetes and treatment switching strategies
- Evaluating weight-loss approaches for overweight and obesity
- Studying treatment effectiveness and safety in metabolic disease
These studies reflect a strong interest in better long-term management of chronic metabolic disease and its complications.
Nervous System Diseases and Hormonal Diseases
Research at this site also includes studies of Diabetic Peripheral Neuropathic Pain, a painful nerve complication of diabetes. The goal is to evaluate whether new treatments can reduce pain and improve quality of life for patients living with this condition.
- Investigating pain relief for Diabetic Peripheral Neuropathic Pain
- Assessing efficacy and tolerability of emerging therapies
- Supporting better symptom control in diabetic nerve disease
This area highlights the site’s focus on complications of metabolic disease that affect daily functioning and comfort.
Skin and Connective Tissue Diseases and Nutritional and Metabolic Diseases
Another important part of the clinical trial portfolio addresses diabetic foot ulcers, where researchers are examining whether new topical treatments can improve wound healing and wound closure. These studies aim to strengthen care for difficult-to-heal ulcers in people with diabetes.
- Evaluating healing outcomes in diabetic foot ulcers
- Testing safety and tolerability of new wound treatments
- Improving recovery for chronic diabetic skin complications
The work combines wound care and metabolic disease research to address a major complication of long-standing diabetes.
Obesity and Weight-Related Metabolic Research
Clinical trials at this private practice site in Munster also explore treatments for obesity and overweight, including options for people with and without Type 2 Diabetes. The purpose is to determine whether new medicines can help patients achieve meaningful weight reduction and improve related health risks.
- Studying therapies for obesity and overweight
- Comparing treatment benefit in people with and without diabetes
- Looking at broader health outcomes linked to weight reduction
These trials show a clear emphasis on metabolic health, with a focus on both disease control and prevention of complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 78 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 78 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB4active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S10trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut fuer Diabetesforschung Muenster GmbH
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) | Novartis Pharma AG | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 78 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 6 | Unknown | 2019-05-02 | 2025-02-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.